Gabelli Funds’s Standard BioTools LAB Stock Holding History

Gabelli Funds’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-20,618	Closed	-$23K	–	1238
2022 Q3	$23K	Hold	20,618	–	–	﹤0.01%	1234
2022 Q2	$33K	Hold	20,618	–	–	﹤0.01%	1265
2022 Q1	$74K	Hold	20,618	–	–	﹤0.01%	1293
2021 Q4	$81K	Buy	+20,618	New	+$96.5K	﹤0.01%	1310
2021 Q2	–	Sell	-49,950	Closed	-$226K	–	1366
2021 Q1	$226K	Buy	+49,950	New	+$274K	﹤0.01%	1211

Other funds holding LAB

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JCP

Jennifer C. Price $75.5M AUM 6.25% 1-Year Est. Return

Gabelli Funds's LAB Position: Q4 2022 in Review

Gabelli Funds sold out of Standard BioTools (LAB) in Q4 2022, closing a stake of 20,618 shares — an estimated $23K sold.

Gabelli Funds first reported a position in LAB in Q1 2021 and held it in 5 quarters. The position peaked at $226K in Q1 2021. 68 funds tracked by Wall St. Rank hold LAB as of Q4 2022.

Gabelli Funds reported no remaining Standard BioTools position as of Q4 2022 after selling out during the quarter.
Gabelli Funds sold 20,618 Standard BioTools shares in Q4 2022, an estimated $23K.
Gabelli Funds first reported a position in Standard BioTools in Q1 2021 and held it in 5 quarters.
Gabelli Funds's Standard BioTools position peaked at $226K in Q1 2021.
68 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2022.

Based on Gabelli Funds's 13F filing for Q4 2022, filed 13 Feb 2023.